Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although thrombosis is considered the cardinal feature of the antiphospholipid syndrome, chronic vascular lesions are common, particularly in patients with life-threatening complications. In patients who require transplantation, vascular lesions often recur. The molecular pathways involved in the vasculopathy of the antiphospholipid syndrome are unknown, and adequate therapies are lacking. METHODS: We used double immunostaining to evaluate pathway activation in the mammalian target of rapamycin complex (mTORC) and the nature of cell proliferation in the vessels of patients with primary or secondary antiphospholipid syndrome nephropathy. We also evaluated autopsy specimens from persons who had catastrophic antiphospholipid syndrome. The molecular pathways through which antiphospholipid antibodies modulate the mTORC pathway were evaluated in vitro, and potential pharmacologic inhibitors were also tested in vitro. Finally, we studied the effect of sirolimus in kidney-transplant recipients with the antiphospholipid syndrome. RESULTS: The vascular endothelium of proliferating intrarenal vessels from patients with antiphospholipid syndrome nephropathy showed indications of activation of the mTORC pathway. In cultured vascular endothelial cells, IgG antibodies from patients with the antiphospholipid syndrome stimulated mTORC through the phosphatidylinositol 3-kinase (PI3K)-AKT pathway. Patients with antiphospholipid syndrome nephropathy who required transplantation and were receiving sirolimus had no recurrence of vascular lesions and had decreased vascular proliferation on biopsy as compared with patients with antiphospholipid antibodies who were not receiving sirolimus. Among 10 patients treated with sirolimus, 7 (70%) had a functioning renal allograft 144 months after transplantation versus 3 of 27 untreated patients (11%). Activation of mTORC was also found in the vessels of autopsy specimens from patients with catastrophic antiphospholipid syndrome. CONCLUSIONS: Our results suggest that the mTORC pathway is involved in the vascular lesions associated with the antiphospholipid syndrome. (Funded by INSERM and others.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Oxidative stress and subsequent mTOR activation occurs in various rheumatic diseases257–259.”
From The role of mitochondria in rheumatic diseases (2022) · cites this paper as [257]
Citations
Cites
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
Vlahos, C. J., Matter, W. F., Hui, K. Y., & Brown, R. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37680-9 · Cited by 3,240
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Levine, J. S., Branch, D. W., & Rauch, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmra002974 · Cited by 1,543
Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199
Eisen, H. J., Tuzcu, E. M., Dorent, R., Kobashigawa, J., Mancini, D., Valantine-von Kaeppler, H. A., Starling, R. C., Sørensen, K., Hummel, M., Lind, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022171 · Cited by 1,198
Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF
Ferns, G. A. A., Raines, E. W., Sprugel, K. H., Motani, A. S., Reidy, M. A., & Ross, R. (1991) · Science · doi:10.1126/science.1653454 · Cited by 1,065
Sousa, J. E., Costa, M. A., Abizaid, A. C., Rensing, B. J., Abizaid, A. S., Tanajura, L. F., Kozuma, K., Van Langenhove, G., Sousa, A. G. M. R., Falotico, R., et al. (2001) · Circulation · doi:10.1161/hc4201.098056 · Cited by 672
Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease
Serra, A. L., Poster, D., Kistler, A. D., Krauer, F., Raina, S., Young, J., Rentsch, K. M., Spanaus, K. S., Senn, O., Kristanto, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907419 · Cited by 571
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice
Gödel, M., Hartleben, B., Herbach, N., Liu, S., Zschiedrich, S., Lu, S., Debreczeni-Mór, A., Lindenmeyer, M. T., Rastaldi, M.-P., Hartleben, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44774 · Cited by 547
Research works printed but not linked: 1
- Alarcon-Segovia D, 1989, J Rheumatol, 16, 762
Cited by
Diagnosis and management of the antiphospholipid syndrome
Garcia, D., & Erkan, D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705454 · Cited by 819
Targeted therapy in patients with PIK3CA-related overgrowth syndrome
Venot, Q., Blanc, T., Rabia, S. H., Berteloot, L., Ladraa, S., Duong, J.-P., Blanc, E., Johnson, S. C., Hoguin, C., Boccara, O., et al. (2018) · Nature · doi:10.1038/s41586-018-0217-9 · Cited by 589
Self-citationLai, Z.-W., Kelly, R., Winans, T., Marchena, I., Shadakshari, A., Yu, J., Dawood, M., Garcia, R., Tily, H., Francis, L., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30485-9 · Cited by 412
Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases
Perl, A. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.172 · Cited by 332
Regulatory T cells in the treatment of disease
Sharabi, A., Tsokos, M. G., Ding, Y., Malek, T. R., Klatzmann, D., & Tsokos, G. C. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.148 · Cited by 297
Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management
Knight, J. S., Branch, D. W., & Ortel, T. L. (2023) · BMJ · doi:10.1136/bmj-2021-069717 · Cited by 265
Partial Epithelial-to-Mesenchymal Transition and Other New Mechanisms of Kidney Fibrosis
Lovisa, S., Zeisberg, M., & Kalluri, R. (2016) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.06.004 · Cited by 255
Alijotas-Reig, J., Esteve-Valverde, E., Ferrer-Oliveras, R., Sáez-Comet, L., Lefkou, E., Mekinian, A., Belizna, C., Ruffatti, A., Tincani, A., Marozio, L., et al. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.12.006 · Cited by 211
Cervera, R., Rodríguez-Pintó, I., & Espinosa, G. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.05.007 · Cited by 217
Perl, A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12756 · Cited by 218
Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances
Sciascia, S., Amigo, M.-C., Roccatello, D., & Khamashta, M. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.124 · Cited by 209
The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus
Ünlü, O., Zuily, S., & Erkan, D. (2019) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2015.0085 · Cited by 207
Sammaritano, L. R. (2020) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.101463 · Cited by 194
Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome
Knight, J. S., & Kanthi, Y. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00916-w · Cited by 191
“The molecular pathways that license these lesions are for the most part unknown, although one yet-to-be-reproduced report posited that the mTOR/Akt pathway is an important mediator of APS nephropathy and therefore a potential pharmacologic target via clinically available agents such as sirolimus [187].”
BackgroundResultInfluentialRoles of mTOR complexes in the kidney: implications for renal disease and transplantation
Fantus, D., Rogers, N. M., Grahammer, F., Huber, T. B., & Thomson, A. W. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.108 · Cited by 208
The antiphospholipid syndrome in patients with systemic lupus erythematosus
Pons-Estel, G. J., Andreoli, L., Scanzi, F., Cervera, R., & Tincani, A. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.10.004 · Cited by 201
“Compared to standard therapy, patients using Sirolimus had a higher rate of functional transplantation and lower rate of vascular lesions [131].”
BackgroundResultRovin, B. H., Caster, D. J., Cattran, D. C., Gibson, K. L., Hogan, J. J., Moeller, M. J., Roccatello, D., Cheung, M., Wheeler, D. C., Winkelmayer, W. C., et al. (2019) · Kidney International · doi:10.1016/j.kint.2018.11.008 · Cited by 185
“Mammalian target of rapamycin inhibition increased kidney transplant survival in patients with a history of APS nephropathy, but further studies are needed in native kidneys.(144)”
BackgroundCorban, M. T., Duarte-Garcia, A., McBane, R. D., Matteson, E. L., Lerman, L. O., & Lerman, A. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.058 · Cited by 181
Kato, H., & Perl, A. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40380 · Cited by 182
“Activation of mTOR also plays a central role in Tcell dysfunction in SLE (11), as has been supported by several independent lines of evidence: 1) mTOR activity is increased in the Tcells of SLE patients (12) and mice with SLE (13); 2) mTOR controls T cell specification during cell development (9,14) and controls the s…”
BackgroundThe Potential Role of Trained Immunity in Autoimmune and Autoinflammatory Disorders
Arts, R. J. W., Joosten, L. A. B., & Netea, M. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00298 · Cited by 177
The PI3K/Akt/PTEN/mTOR Pathway: A Fruitful Target for Inducing Cell Death in Rheumatoid Arthritis?
Malemud, C. J. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.55 · Cited by 174
Zuily, S., Cohen, H., Isenberg, D. A., Woller, S. C., Crowther, M. A., Dufrost, V., Wahl, D. G., Doré, C. J., Cuker, A. C., Carrier, M., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14935 · Cited by 168
Pignatelli, P., Ettorre, E., Menichelli, D., Pani, A., Violi, F., & Pastori, D. (2020) · Haematologica · doi:10.3324/haematol.2019.221945 · Cited by 160
“A first example is represented by mTOR inhibitors; these were found to reduce the onset of new vascular lesions after transplantation in patients with APS nephropathy.(81) Monoclonal antibodies such as rituximab(82) (anti-CD20 agent) and eculizumab(23) (anti-C5 agent) are currently administrated to manage noncriteria…”
BackgroundCyclin G1 and TASCC regulate kidney epithelial cell G 2 -M arrest and fibrotic maladaptive repair
Canaud, G., Brooks, C. R., Kishi, S., Taguchi, K., Nishimura, K., Magassa, S., Scott, A., Hsiao, L.-L., Ichimura, T., Terzi, F., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav4754 · Cited by 139
Self-citationGkirtzimanaki, K., Kabrani, E., Nikoleri, D., Polyzos, A., Blanas, A., Sidiropoulos, P. I., Makrigiannakis, A., Bertsias, G. K., Boumpas, D. T., & Verginis, P. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.09.001 · Cited by 140
Oaks, Z., Winans, T., Caza, T., Fernandez, D., Liu, Y., Landas, S. K., Banki, K., & Perl, A. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39791 · Cited by 136
“cin in that study (13) met the diagnostic criteria for SLE”
BackgroundNon-HLA antibodies against endothelial targets bridging allo- and autoimmunity
Dragun, D., Catar, R. A., & Philippe, A. (2016) · Kidney International · doi:10.1016/j.kint.2016.03.019 · Cited by 126
Pathogenesis and management of antiphospholipid syndrome
Arachchillage, D. J., & Laffan, M. (2017) · British Journal of Haematology · doi:10.1111/bjh.14632 · Cited by 137
“Catastrophic APS (CAPS) is a rare and potentially fatal variant of APS characterized by sudden onset of extensive microvascular thrombosis at multiple sites leading to multiorgan failure (Cervera et al, 2014).”
BackgroundThe PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19
Basile, M. S., Cavalli, E., McCubrey, J. A., Hernández‐Bello, J., Muñóz-Valle, J. F., Fagone, P., & Nicoletti, F. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.11.002 · Cited by 118
“Interestingly, activation of the mTOR pathway was observed in the vascular endothelium of proliferating intrarenal vessels from patients with APS nephropathy.(71) In addition, patients with APS nephropathy who underwent transplantation and were receiving rapamycin had no recurrence of vascular lesions and showed lower…”
BackgroundResultPetri, M. (2020) · Translational research · doi:10.1016/j.trsl.2020.04.006 · Cited by 130
New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation
Waldner, M., Fantus, D., Solari, M. G., & Thomson, A. W. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12893 · Cited by 106
Alpelisib administration reduced lymphatic malformations in a mouse model and in patients
Delestre, F., Venot, Q., Bayard, C., Fraissenon, A., Ladraa, S., Hoguin, C., Chapelle, C., Yamaguchi, J., Cassaca, R., Zerbib, L., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abg0809 · Cited by 101
Self-citationAntiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy
Fleetwood, T., Cantello, R. M., & Comi, C. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.01001 · Cited by 107
“Interestingly, those receiving sirolimus had no recurrence of vascular lesions and showed decreased vascular proliferation on biopsy (173).”
BackgroundAntiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment
Tektonidou, M. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01181 · Cited by 93
“showed that among the 10 patients who received mTOR pathway inhibition treatment, 7 patients (70%) had a functioning allograft 10 years after transplantation versus 3 (11%) of 27 untreated patients, and the effect of treatment was independent of anticoagulation treatment (53).”
BackgroundOaks, Z., Winans, T., Huang, N., Bánki, K., & Perl, A. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0622-8 · Cited by 95
“There is some debate on which cell type better defines SLE pathogenesis, but a common finding in T cells, B cells, macrophages, hepatocytes, and reno-vascular cells is mTOR activation [8].”
BackgroundB7–1 Blockade Does Not Improve Post–Transplant Nephrotic Syndrome Caused by Recurrent FSGS
Delville, M., Baye, E., Dürrbach, A., Audard, V., Kofman, T., Braun, L., Olagne, J., Nguyen, C., Deschênes, G., Moulin, B., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015091002 · Cited by 87
Self-citationAntiphospholipid syndrome – an update
Linnemann, B. (2018) · VASA · doi:10.1024/0301-1526/a000723 · Cited by 90
mTOR: A Potential Therapeutic Target in Osteoarthritis?
Pal, B., Endisha, H., Zhang, Y., & Kapoor, M. (2015) · Drugs in R&D · doi:10.1007/s40268-015-0082-z · Cited by 90
“The mTOR pathway has also been shown to be involved in the development of vascular lesions associated with antiphospholipid syndrome, an autoimmune disease [91].”
BackgroundVelásquez, M., Rojas, M., Abrahams, V. M., Escudero, C., & Cadavid, Á. P. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01840 · Cited by 82
“The authors concluded that the mTOR signaling pathway is involved in the development of the endothelial dysfunction that result in the clinical manifestations of APS (Figure 1B) (Canaud et al., 2014).”
BackgroundThe role of mitochondria in rheumatic diseases
Becker, Y. L. C., Duvvuri, B., Fortin, P. R., Lood, C., & Boilard, E. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00834-z · Cited by 81
Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus
Mizui, M., & Tsokos, G. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00786 · Cited by 89
“Moreover, rapamycin can block the production of antiphospholipid antibody in lupus-prone mice (91) and enhance renal allograft survival of antiphospholipid syndrome patients (92).”
BackgroundCellular and Molecular Mechanisms of Anti-Phospholipid Syndrome
Radic, M. Z., & Pattanaik, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00969 · Cited by 77
“IgG antibodies from APS patients, when incubated with vascular endothelial cells, stimulate the mammalian/mTOR through the phosphatidylinositol 3-kinase–AKT pathway (120) leading to cell proliferation.”
BackgroundAdvances in systemic lupus erythematosus pathogenesis via mTOR signaling pathway
He, J., Ma, J., Ren, B., & Liu, A. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.09.022 · Cited by 71
Chighizola, C. B., Ubiali, T., & Meroni, P. L. (2015) · Journal of Immunology Research · doi:10.1155/2015/951424 · Cited by 71
“…is burdened by significant side effects: such poor safety profile of drugs acting on the coagulation cascade explains why novel therapeutic approaches are currently under investigation, in order to identify pharmacological tools specifically counteracting aPL-mediated prothrombotic effects.”
BackgroundBrocklebank, V., & Kavanagh, D. (2017) · Clinical Kidney Journal · doi:10.1093/ckj/sfx081 · Cited by 66
The treatment of anti-phospholipid syndrome: A comprehensive clinical approach
Chighizola, C. B., Andréoli, L., Gerosa, M., Tincani, A., Ruffatti, A., & Meroni, P. L. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.02.003 · Cited by 70
“The mTOR inhibitor sirolimus has been prescribed to patients with APS nephropathy requiring kidney transplantation: compared to standard regimen, it allowed a higher rate of functioning allograft and a decreased vascular proliferation on biopsy compared with the standard regimen arm [97].”
MethodKhamashta, M. A., Taraborelli, M., Sciascia, S., & Tincani, A. (2016) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2016.04.002 · Cited by 81
“Recent evidence indicates that vasculopathy, enhanced mainly by severe intimal hyperplasia, can also play a role in arterial vascular occlusion (due to stenotic lesions) and pregnancy morbidity [3].”
An update on the management of antiphospholipid syndrome
Rodziewicz, M., & D’Cruz, D. P. (2020) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x20910855 · Cited by 69
Antiphospholipid syndrome and kidney disease
Bienaimé, F., Legendre, C. M., Terzi, F., & Canaud, G. (2016) · Kidney International · doi:10.1016/j.kint.2016.06.026 · Cited by 68
Self-citationZuily, S., Domingues, V., Selton‐Suty, C., Eschwège, V., Bertoletti, L., Chaouat, A., Chabot, F., Regnault, V., Horn, E. M., Erkan, D., et al. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.04.003 · Cited by 62
Renal Involvement in Antiphospholipid Syndrome
Turrent-Carriles, A., Herrera-Felix, J. P., & Amigo, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01008 · Cited by 61
“In patients with CAPS associated with SLE, cyclophosphamide may be effective.”
BackgroundInfluentialImmunometabolic Pathways and Its Therapeutic Implication in Autoimmune Diseases
Wang, T., Jiao, Y., & Zhang, X. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08821-6 · Cited by 69
Targeting thromboinflammation in antiphospholipid syndrome
Salet, D. M., Bekkering, S., Middeldorp, S., & van den Hoogen, L. L. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2022.12.002 · Cited by 62
Chock, Y. P. E., Moulinet, T., Dufrost, V., Erkan, D., Wahl, D. G., & Zuily, S. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102395 · Cited by 62
Hypercoagulability in Kidney Transplant Recipients
Parajuli, S., Lockridge, J. B., Langewisch, E. D., Norman, D. J., & Kujovich, J. L. (2015) · Transplantation · doi:10.1097/tp.0000000000000887 · Cited by 56
“Renal transplant patient with APLS who received the mTOR inhibitor, sirolimus had no evidence of recurrent vascular lesions on biopsy compared to APLA-positive patients not receiving sirolimus, suggesting inhibition of the mTORC pathway may prevent graft loss in this group.(55) It remains difficult to predict thrombot…”
BackgroundClinical Experience of Sirolimus Regarding Efficacy and Safety in Systemic Lupus Erythematosus
Eriksson, P., Wallin, P., & Sjöwall, C. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00082 · Cited by 55
Catastrophic antiphospholipid syndrome: The current management approach
Rodríguez‐Pintó, I., Espinosa, G., & Cervera, R. (2016) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2016.07.004 · Cited by 58
Metabolic Targets for Treatment of Autoimmune Diseases
Piranavan, P., Bhamra, M. S., & Perl, A. (2020) · Immunometabolism · doi:10.20900/immunometab20200012 · Cited by 56
“Given the newly uncovered role for mTOR in production of antiphospholipid antibodies outside [94] or within the context of SLE [95,96], KYN should be considered a metabolic trigger of thrombosis through the tissue factor-plasminogen activator inhibitor 1 axis (Figure 2) [93].”
BackgroundAn Update on Childhood-Onset Takayasu Arteritis
Aeschlimann, F. A., Yeung, R. S. M., & Laxer, R. M. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.872313 · Cited by 53
“Cardiac disease 3 (21)a 3 (18)b 1 (5) 8 (20)c 13 (18)d 4 (14)e 3 (27)f 2 (18) NR 1 (6)g 25 (25)h o 18 (15) 0 NR 81/475 (17) 52/230 (23)”
BackgroundInfluentialmTOR inhibitors may benefit kidney transplant recipients with mitochondrial diseases
Johnson, S. C., Martinez, F., Bitto, A., González, B., Tazaerslan, C., Cohen, C., Delaval, L., Timsit, J., Knebelmann, B., Terzi, F., et al. (2018) · Kidney International · doi:10.1016/j.kint.2018.08.038 · Cited by 53
Self-citationJi, L., Xie, W., & Zhang, Z. (2020) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.07.006 · Cited by 53
Jacobs, L., Wauters, N., Lablad, Y., Morelle, J., & Taghavi, M. (2024) · Antibodies · doi:10.3390/antib13010021 · Cited by 52
“Sirolimus inhibits the mTOR signaling pathway, a therapeutic target in vascular lesions associated with APS nephropathy [79–81], and appears promising in CAPS, but there is currently insufficient data to recommend its use.”
BackgroundThe Role of Complement Inhibition in Thrombotic Angiopathies and Antiphospholipid Syndrome
Erkan, D., & Salmon, J. E. (2016) · Turkish Journal of Hematology · doi:10.4274/tjh.2015.0197 · Cited by 52
“Recently, it has been shown that in APS patients these vascular renal lesions are associated with the activation of the mammalian target of rapamycin pathway [29].”
BackgroundPathophysiology of Antiphospholipid Syndrome
Green, D. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1701-2809 · Cited by 50
Capozzi, A., Manganelli, V., Riitano, G., Caissutti, D., Longo, A., Garofalo, T., Sorice, M., & Misasi, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030891 · Cited by 54
“Recently, another signaling related to vasculopathy of APS has been described, in which aPLs directly activate the mammalian target of the rapamycin complex (mTORC) pathway in intrarenal vessels of patients with primary and secondary APS nephropathy [100].”
Emerging Therapies in Antiphospholipid Syndrome
ANDRADE, D. C. O. D., & Tektonidou, M. G. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0566-z · Cited by 49
Hysa, E., Cutolo, C. A., Gotelli, E., Paolino, S., Cimmino, M. A., Pacini, G., Pizzorni, C., Sulli, A., Smith, V. M., & Cutolo, M. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102796 · Cited by 51
Hadjadj, J., Canaud, G., Mirault, T., Samson, M., Bruneval, P., Régent, A., Goulvestre, C., Witko‐Sarsat, V., Costedoat-Chalumeau, N., Guillevin, L., et al. (2018) · Rheumatology · doi:10.1093/rheumatology/key017 · Cited by 47
Self-citationClinical Insights into Diffuse Alveolar Hemorrhage in Antiphospholipid Syndrome
Stoots, S. A., Lief, L., & Erkan, D. (2019) · Current Rheumatology Reports · doi:10.1007/s11926-019-0852-7 · Cited by 47
Antiphospholipid syndrome: an update
Merashli, M., Noureldine, M. H. A., Uthman, I. W., & Khamashta, M. A. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12449 · Cited by 47
Zuily, S., Clerc‐Urmès, I., Bauman, C., ANDRADE, D. C. O. D., Sciascia, S., Pengo, V., Tektonidou, M. G., Ugarte, A., Gerosa, M., Belmont, M. H., et al. (2020) · Lupus · doi:10.1177/0961203320940776 · Cited by 44
Expert Perspective: Management of Microvascular and Catastrophic Antiphospholipid Syndrome
Erkan, D. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41891 · Cited by 47
Hollerbach, A., Müller‐Calleja, N., Ritter, S., Häuser, F., Canisius, A., Orning, C., Jurk, K., & Lackner, K. J. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1685453 · Cited by 43
Rethinking antiphospholipid syndrome to guide future management and research
Knight, J. S., & Erkan, D. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01110-y · Cited by 42
“The molecular pathways that promote these changes have not been intensively studied, with a single report published in 2014 implicating the mechanistic target of rapamycin (mTOR)–Akt pathway as an important mediator of aPL nephropathy and therefore a potential pharmacological target 16 .”
Update on the pathogenesis and treatment of the antiphospholipid syndrome
Chighizola, C. B., Raschi, E., Borghi, M. O., & Meroni, P. L. (2015) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000200 · Cited by 42
Kotzen, E., Roy, S., & Jain, K. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.08.012 · Cited by 44
Misasi, R., Longo, A., Recalchi, S., Caissutti, D., Riitano, G., Manganelli, V., Garofalo, T., Sorice, M., & Capozzi, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218411 · Cited by 51
“pathway [37], leading to cell proliferation.”
BackgroundCaza, T. N., Wijewardena, C., Al-Rabadi, L. F., & Perl, A. (2022) · Translational research · doi:10.1016/j.trsl.2022.03.004 · Cited by 41
mTOR pathway activation in large vessel vasculitis
Maciejewski‐Duval, A., Comarmond, C., Leroyer, A. S., Zaidan, M., Joncour, A. L., Desbois, A. C., Fouret, J.-P., Koskas, F., Cluzel, P., Garrido, M., et al. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.07.013 · Cited by 40
Management of Non-criteria Manifestations in Antiphospholipid Syndrome
Xourgia, E., & Tektonidou, M. G. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00935-2 · Cited by 40
Arterial wall fibrosis in Takayasu arteritis and its potential for therapeutic modulation
Misra, D. P., Singh, K., Sharma, A., & Agarwal, V. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1174249 · Cited by 40
“mTORC1 inhibition has antifibrotic effects in kidneys affected with antiphospholipid antibody syndrome (25).”
BackgroundXia, L., Zhou, H., Wang, T., Xie, Y., Wang, T., Wang, X., & Yan, J. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.05.023 · Cited by 40
“Canaud and colleagues also suggested that aPL activate the mTORC pathway in renal vascular ECs and then trigger thrombosis and vasculopathy in APS [14].”
BackgroundInfluentialTreatment of antiphospholipid syndrome beyond anticoagulation
Dobrowolski, C., & Erkan, D. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.03.001 · Cited by 36
Cheng, C., Cheng, G.-Y., Denas, G., & Pengo, V. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100788 · Cited by 39
Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management
Scheen, M., Adedjouma, A., Estève, E., Buob, D., Abisror, N., Planche, V., Fain, O., Boffa, J. J., de Seigneux, S., MEKINIAN, A., et al. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103072 · Cited by 36
Manganelli, V., Truglia, S., Capozzi, A., Alessandri, C., Riitano, G., Spinelli, F. R., Ceccarelli, F., Mancuso, S., Garofalo, T., Longo, A., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00460 · Cited by 37
“This finding is not surprising since it has already reported that HMGB1/RAGE knockdown is able to induce mTOR phosphorylation (33, 34), but may contribute to clarify the effect in APS patients of drugs able to induce mTOR blockade (35).”
BackgroundManagement of Thrombotic Antiphospholipid Syndrome
Chighizola, C. B., Raimondo, M. G., & Meroni, P. L. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0036-1597282 · Cited by 39
Ripoll, V. M., Pregnolato, F., Mazza, S., Bodio, C., Grossi, C., McDonnell, T. C. R., Pericleous, C., Meroni, P. L., Isenberg, D. A., Rahman, A., et al. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.07.002 · Cited by 36
Metabolic pathways mediate pathogenesis and offer targets for treatment in rheumatic diseases
Wyman, B., & Perl, A. (2019) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000687 · Cited by 37
“These patients exhibit reduced renal lesions, stable GFR, and improved graft survival, compared to patients that did not receive sirolimus [62].”
BackgroundMüller‐Calleja, N., Hollerbach, A., Häuser, F., Canisius, A., Orning, C., & Lackner, K. J. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13865 · Cited by 36
Catastrophic antiphospholipid syndrome and pregnancy
Silver, R. M. (2017) · Seminars in Perinatology · doi:10.1053/j.semperi.2017.11.006 · Cited by 37
Dilemmas in the diagnosis and management of antiphospholipid syndrome
Manning, J. E., & Arachchillage, D. J. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.03.027 · Cited by 38
Uludağ, G., Onghanseng, N., Tran, A. N. T., Hassan, M., Halim, M. S., Sepah, Y. J., Diana, V., & Nguyen, Q. D. (2021) · Journal of Ophthalmic Inflammation and Infection · doi:10.1186/s12348-021-00240-8 · Cited by 35
Catar, R. A., Wischnewski, O., Chen, L., Heidecke, H., Rutz, C., Schülein, R., Dragun, D., Philippe, A., & Kusch, A. (2021) · Kidney International · doi:10.1016/j.kint.2021.09.029 · Cited by 38
Barbhaiya, M., Taghavi, M., Zuily, S., Domingues, V., Chock, E. Y., Tektonidou, M. G., Erkan, D., & Seshan, S. V. (2023) · The Journal of Rheumatology · doi:10.3899/jrheum.2022-1200 · Cited by 33
Catastrophic Antiphospholipid Syndrome: Candidate Therapies for a Potentially Lethal Disease
Ünlü, O., & Erkan, D. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-102529 · Cited by 33
Insights into the diagnosis and pathogenesis of the antiphospholipid syndrome
Noureldine, M. H. A., Nour‐Eldine, W., Khamashta, M. A., & Uthman, I. W. (2018) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2018.08.004 · Cited by 37
AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game
Canaud, G., Legendre, C., & Terzi, F. (2015) · Lupus · doi:10.1177/0961203315569336 · Cited by 32
Self-citationTargeted therapy for capillary-venous malformations
Zerbib, L., Ladraa, S., Fraissenon, A., Bayard, C., Firpion, M., Venot, Q., Protic, S., Hoguin, C., Thomas, A., Fraitag, S., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01862-9 · Cited by 41
Self-citationDufour, I., Venot, Q., Aydın, S., Demoulin, N., Canaud, G., & Morelle, J. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.08.032 · Cited by 32
Self-citation
Metadata
- Authors
- Canaud, G., Bienaimé, F., Tabarin, F., Bataillon, G., Seilhean, D., Noël, L.-H., Dragon-Durey, M.-A., Snanoudj, R., Friedlander, G., Halbwachs-Mecarelli, L., Legendre, C., & Terzi, F.
- Affiliations
- Hôpital Necker-Enfants Malades (FR)
- Inserm (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-24
- Volume
- 371
- Issue
- 4
- Pages
- 303-312
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2151319957
- Cited by
- 355
- References
- 38
- Citations by year
- 2026: 20 · 2025: 20 · 2024: 34 · 2023: 29 · 2022: 22 · 2021: 26 · 2020: 26 · 2019: 35 · 2018: 44 · 2017: 33 · 2016: 34 · 2015: 25 · 2014: 7
- FWCI
- 27.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Keywords
- antiphospholipid syndrome, rapamycin, antiphospholipid antibodies, PI3K/Akt signaling, vascular endothelial cell proliferation, kidney transplantation, catastrophic antiphospholipid syndrome, renal allograft survival, vascular lesions
- MeSH terms
- Adult, Analysis of Variance, Autopsy, Endothelium, Vascular, Female, Humans, Immunoglobulin G, Immunosuppressive Agents, Kidney, Kidney Diseases, Male, Middle Aged, Kidney Transplantation, Antiphospholipid Syndrome, Antibodies, Antiphospholipid, Sirolimus, Cell Proliferation, Metabolic Networks and Pathways, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.